<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096187</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000390347</org_study_id>
    <secondary_id>GOG-0217</secondary_id>
    <secondary_id>GOG-UC0205</secondary_id>
    <secondary_id>LILLY-H3E-US-JMGR</secondary_id>
    <nct_id>NCT00096187</nct_id>
  </id_info>
  <brief_title>Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy</brief_title>
  <official_title>A Phase II Trial of Pemetrexed (ALIMTA®, LY231514, IND #40061) as Salvage Therapy for Failed Low Risk Gestational Trophoblastic Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>GOG Foundation</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to&#xD;
      stop tumor cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating&#xD;
      patients with recurrent or persistent low-risk gestational trophoblastic tumor after a molar&#xD;
      pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the activity of pemetrexed disodium as salvage therapy in patients with&#xD;
           persistent or recurrent low-risk post-molar gestational trophoblastic tumor that failed&#xD;
           prior dactinomycin or methotrexate.&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21&#xD;
      days in the absence of unacceptable toxicity or disease progression or until tumor marker&#xD;
      levels (human chorionic gonadotropin [hCG]) become normal. Patients receive 2 additional&#xD;
      courses beyond the attainment of a normal hCG.&#xD;
&#xD;
      Beginning 7 days before and continuing until 3 weeks after the last dose of pemetrexed&#xD;
      disodium, patients also receive oral folic acid daily and cyanocobalamin (vitamin B_12)&#xD;
      intramuscularly every 9 weeks.&#xD;
&#xD;
      Patients are followed every 2 weeks for 2 months and then monthly for 10 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 17-55 patients will be accrued for this study within 20-50&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>July 2005</start_date>
  <primary_completion_date type="Actual">July 23, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Activity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Gestational Trophoblastic Tumor</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed disodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of low-risk post-molar gestational trophoblastic tumor, defined as 1 of the&#xD;
             following:&#xD;
&#xD;
               -  Increasing human chorionic gonadotropin (hCG) levels on ≥ 3 consecutive&#xD;
                  measurements taken over ≥ a 2-week period&#xD;
&#xD;
               -  Less than 10% decrease of hCG levels on 4 measurements taken over ≥ a 3-week&#xD;
                  period&#xD;
&#xD;
          -  Persistent or recurrent disease&#xD;
&#xD;
          -  Histologically confirmed complete or partial mole on initial evacuation&#xD;
&#xD;
               -  Prior pregnancy ≤ 12 months ago&#xD;
&#xD;
          -  No histologically confirmed choriocarcinoma or placental site trophoblastic tumor on&#xD;
             initial evacuation&#xD;
&#xD;
          -  Failed only 1 prior dactinomycin or methotrexate therapy (with or without leucovorin&#xD;
             calcium)&#xD;
&#xD;
          -  WHO score 2-6&#xD;
&#xD;
          -  No evidence of metastatic disease, except to the lung or vagina, on physical exam,&#xD;
             chemistry, chest X-ray, and ultrasound&#xD;
&#xD;
               -  No liver, spleen, brain, kidney, or gastrointestinal tract metastases&#xD;
&#xD;
               -  No more than 8 metastatic lesions&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  GOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT ≤ 3 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance ≥ 45 mL/min&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  No significant infection&#xD;
&#xD;
          -  No other invasive malignancy within the past 5 years except nonmelanoma skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent prophylactic filgrastim (G-CSF) unless for recurrent neutropenic&#xD;
             complications&#xD;
&#xD;
          -  No concurrent prophylactic thrombopoietic agents unless for recurrent grade 4&#xD;
             thrombocytopenia&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 7 days since prior dactinomycin or methotrexate (with or without leucovorin&#xD;
             calcium) and recovered&#xD;
&#xD;
          -  No prior pemetrexed disodium&#xD;
&#xD;
          -  No other prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 14 days since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy to ≥ 25% of the bone marrow&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No nonsteroidal anti-inflammatory drugs or salicylates for 2 days (or 5 days for drugs&#xD;
             with a long half-life) before, during, and for 2 days after pemetrexed disodium&#xD;
             administration&#xD;
&#xD;
               -  Concurrent low-dose aspirin (≤ 325 mg/day) allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David S. Miller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Simmons Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Allan Covens, MD</last_name>
    <affiliation>Toronto Sunnybrook Regional Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Saint Joseph Medical Center - Burbank</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hinsdale Hematology Oncology Associates</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Regional Health Center</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hulston Cancer Center at Cox Medical Center South</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at Cooper - Voorhees</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blumenthal Cancer Center at Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232-2861</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilson Medical Center</name>
      <address>
        <city>Wilson</city>
        <state>North Carolina</state>
        <zip>27893-3428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles M. Barrett Cancer Center at University Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital Cancer Care</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214-3998</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillcrest Cancer Center at Hillcrest Hospital</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake/University Ireland Cancer Center</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Cancer Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosenfeld Cancer Center at Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19612-6052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Southwest Cancer and Research Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79415-3364</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>November 9, 2004</study_first_submitted>
  <study_first_submitted_qc>November 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2004</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <keyword>low risk metastatic gestational trophoblastic tumor</keyword>
  <keyword>recurrent gestational trophoblastic tumor</keyword>
  <keyword>nonmetastatic gestational trophoblastic tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trophoblastic Neoplasms</mesh_term>
    <mesh_term>Gestational Trophoblastic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

